Mastic gum aided amoxicillin trihydrate gastro retentive mucoadhesive microspheres: In vivo evaluation

H. B. M. Sowjanya¹ and H. A. Ahad²*

¹Department of Pharmaceutical Sciences, Jawaharlal Nehru Technological University, Anantapur, Ananthapuramu-515001, Andhra Pradesh, India.
²Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, K. R. Palli Cross, Ananthapuramu-515721, Andhra Pradesh, India

Abstract

The primary objective of the study is to test gastro retentive mucoadhesive Amoxicillin trihydrate (ATH) microspheres for various in vivo properties. Several metrics were used to assess the improved ATH Mastic gum mucoadhesive microspheres (AMMM) in vitro. In vivo testing was conducted using formula-8 (AMMM-8), as suggested by prior study results by Soujanya et al., 2022. Four healthy rabbits of both sexes were used to assess the availability of plasma medicines. Pharmacokinetic parameters were measured in plasma samples. The study revealed that in vivo animal studies in rabbits showed good drug levels of ATH. After a single dose of formulation AMMM-8 (44.28mg/kg), the symmetrical mean C max (25.69±0.11µg/ml) t max (6h), AUC (0-1h) (185.1±1.28 µg.h/ml), AUC (0-1h) (269.1±4.68 µg.h/ml), and AUMC (840.42±2.23 µg.h/ml) were better than ATH. According to the findings, ATH reached systemic circulation faster than the pure medication and had acceptable kinetic values.

Keywords: Bioavailability; Kinetics; Microspheres; Rabbits; In vivo.

Introduction

The gastro retentive microsphere is one of the attractive segments in delivering stomach-specific drugs additionally they can be easily prepared and administered (Kousar et al., 2022).

An oral product containing amoxicillin trihydrate (ATH) is semi-synthetic amino penicillin with broad-spectrum bactericidal activity (Limousy et al., 2017). ATH is a white or almost white crystaline powder. Based on its physicomechanical and biopharmaceutical properties, and the pH partition theory, ATH is well absorbed when given orally. In the trihydrate form, amoxicillin is soluble in water, resulting in slight hygroscopic behavior.

Mucoadhesive systems’ effectiveness is greatly influenced by the properties of a polymer (Prabaharan and Gong, 2008). The convenience of taking medicine by mouth is preferred by many patients (Andrews et al., 2009). The bioadhesive drive, which is rare and expensive, has been made with a variety of polymers (Hoffman, 2013). Rather than developing synthetic polymers, In the current study, natural polymer was used that can aid mucoadhesion. The authors used mastic gum (MG) in the study of ATH mucoadhesive microspheres (AMMM). MG has been shown to have a healing effect on stomach/peptic ulcers (Miyamoto et al. 2014) and is effective against H. pylori (Dabos et al., 2010; Dimas et al., 2012; Miyamoto et al., 2014). The objective of AMMM is systemic availability at a constant state (Table I). Precision liberation systems are a fantastic choice for quick-acting medications and those that need continuous medication because they are simple to use.
One variable at a time is the main focus of conventional research techniques because it is the most manageable. It is statistically impossible to look at all of these variables at once. Because of their interdependence, the results will be unreliable. The core component of multivariate analysis is the design of experiments (DOE) (Abdul et al., 2020). Partial factors are covered by a treaty in DOE. The DOE's goals include screening and optimization. Every potential combination of the elements is included in a Factorial Design (FD). In FD, a high level is either (+1) or "low" (-1); these two levels are referred to as FD (Shravani et al., 2020). The results of the study were based on the evaluation of AMMM response to discharge ATH using design expert software.

Among all the above formulations, AMMM-8 possesses all the characteristics of an ideal gastro retentive mucoadhesive microsphere including ATH release at 10h (90.4±2.3%), mucoadhesive strength (23.3±0.2 g), drug entrapment efficiency (86.3±1.5%), mucoadhesion time (14.7±0.9h), particle size (42.9±0.1μm) and swelling index (60.3±0.2%). as described by Soujanya et al. (Soujanya and Hindustan, 2022). So, AMMM-8 was subjected to in vivo trials.

Materials and methods

Materials

Merck chemicals provided acetonitrile and o-phosphoric acid, as well as triple glass distilled water (HPLC grade) and analytical grade chemicals. Krishna Rabbit Farms in Bengaluru provided the New Zealand Wistar rabbits for the in vivo study. Animal Ethical Guidelines for Laboratory Investigations were followed during the in vivo study.

The Institutional Animal Ethics Committee (RIPA/2022/ COL-05R) for experimenting. The institute was ratified by CPCSEA (792/ac/05/CPCSEA/008/2022) for performing animal experiments.

In vivo Study

The in vitro studies on numerous evaluation parameters were attained as chosen by Sharma and Co-workers (2015) (Sharma et al., 2015). The authors selected formula-5 (AMMM-8) for in vivo study (Prakash et al., 2008).

In vivo bioavailability study

By using a parallel design, 4 white New Zealand rabbits of any gender (weighing 2-2.5 kg) were haphazardly parted into two groups of identical size. The task was decided upon to match the pharmacokinetics of ATH selected AMMM-8 having 1000 mg of ATH and 100 mg of mastic gum (MG) and 75 mg of Carbopol 934P. Food was removed 10±1 h previous to the in vivo research, and water was provided ad libitum. Rabbits in Group-A were given AMMM-8 orally, while rabbits in Group-B were given pure ATH suspension in water. At 0, 0.5, 1, 2, 4, 6, and 10 h following the therapy, blood samples (2 ml) were collected into heparinized tubes. Centrifugation at 4,000 rpm for 15 min separated the plasma from the heparinized whole blood. Plasma samples were proximately moved to Eppendorf tubes after being separated and stored at -20°C until analysis. HPLC analysis was utilized to determine the drug's plasma concentration, and the following steps were used for HPLC analysis (Purohit et al., 2021; Purohit et al., 2020).

Estimation of ATH in serum samples

ATH in the serum samples was estimated according to the High-Performance Liquid Chromatographic (HPLC) process (Purohit et al., 2020).

Preparation of standard solution and plotting of correction curves

Nagae (Nagae et al., 2007) established the procedure, which was followed with minor changes. 1000 mg ATH (for stock solution A) was properly weighed and moved to a 100 ml volumetric flask, where it was dissolved with the use of sonication in the mobile phase, and the final volume was created using the mobile phase. Working standard solutions were made from these stock solutions using appropriate dilution with mobile phase to obtain concentrations of 15-90 g of ATH (Pushparaj et al., 2018).

Preparation of the spiked plasma sample

This was performed by using a standard procedures (Megoulas et al., 2005; Yu et al., 2005). 250μL of rabbit plasma, 50μL of internal standard, and 10 μL of ATH were pipetted into a 10ml centrifuge tube, and to this 2ml of Acetonitrile was included. 10μL of the supernatant layer was poised (after centrifugation at 3200 rpm for 10min), inserted into HPLC, and chromatogram was obtained (Narenderan et al., 2019).
The mobile phase was a 60:40 (v/v) mixture of freshly made buffer 0.1 percent Acetonitrile and water o-Phosphoric acid, which proved to be an excellent separation mixture. The flow rates were then measured at 0.4, 0.8, 1.0, 1.2, and 1.5 ml/min. Because it provides a superior resolution of the peaks, 1.0 ml/min was chosen for the discovery of ATH at set chromatographic conditions and the detection of 247 nm, with no native nosey composites eluting at ATH retention times (Atici et al., 2017; Beg et al., 2012).

Determination of various pharmacokinetic parameters

Several pharmacokinetic parameters were calculated from the time vs. serum ATH data, including peak concentration (Cₘₐₓ), time at which drug peaks (tₘₐₓ), the area under the curve (AUC), elimination rate constant Kel, biological half-life (t½), percent absorbed at various times, and absorption rate constant (Kₐ). Correction curves were used to determine the peak serum level (Cₘₐₓ) and the time at which the peak was reached (tₘₐₓ). On a semi-logarithmic graph paper, the serum level and time values were plotted. During the elimination phase, the Kel was determined using the slope of the linear line (the best fit linear regression line for the points in the elimination phase was haggard by the process of fewest squares). The constant t½ was derived using the equation t½ = 0.693/Kel. Percent absorbed at different times, and Kₐ was estimated using the Wagner and Nelson equation. Using the trapezoidal rule, the AUC was determined. Using the following eqs. 1 and 2, the remaining area from 10 h to time was determined (Rocha et al., 2019; Sartini et al., 2022; Soares et al., 2021).

In vivo investigation protocol

To Calculate Animal Equivalent Dose (AED) from Human Dose by eq.3 was employed.

Animal equivalent dose calculations were made using the aforementioned equation and a 70 kg average human weight. A (1000 mg). ATH (44.28 mg) per kg body weight of the animal is the calculated Animal Equivalent Dose (AED) (Nair and Jacob, 2016; Shin et al., 2010)

Treatment of animals

Healthy rabbits of both sexes were starved for 24 h. ATH and AMMM-8 were given at a dose of 44.28 mg/kg. Each product was tested a total of four times (n = four). A crossover study was conducted in conjunction with the in vivo trials (fig. 1) (Abdul et al., 2011; Alkharfy et al., 2015).

Blood samples (0.5ml) were taken from rabbits' marginal ear veins, allowed to clot, then centrifuged at 5000 rpm (to separate plasma) and deposited in dry tubes. Before the test, all of the samples were kept in the refrigerator. HPLC was used to determine the quantity of ATH. The plot of time vs. plasma concentration was used to determine peak concentration (Cₘₐₓ), time at which peak concentration occurred (tₘₐₓ), Area under the Curve (AUC), elimination rate constant (Kₐ), half-life (t½), percent absorbed at various periods, and Ka.

Results and discussion

The chromatogram of the plasma sample was taken at 1, 3, 6, and 10th h indicating the presence of ACH in the plasma (fig 2 and table II). The retention time was good at 1st h (4.38 min) with upsurge peak area of 70488 with an asymmetric factor of 1.39.

The HPLC chromatogram shows a linearity of 2-12µg/ml for all the chromatograms. The LOD and LOQ were more at 1st h of the plasma sample with 0.34µg/ml and 1.17µg/ml (Table III).
of any gender (weighing 2-2.5 kg) were haphazardly distributed in the study. By using a parallel design, 4 white New Zealand rabbits were selected (Prakash et al., 2015). The authors selected formula-5 (AMMM-8) having 1000 mg of ATH and 100 mg of Mastic gum aided amoxicillin trihydrate gastro retentive mucoadhesive microspheres.

Material and methods

Solutions of ATH were prepared in 0.9% sodium chloride solution and 1% of carboxymethyl chitosan-g-β-cyclodextrin as mucoadhesive polymer, Span 80, and liquid paraffin. The mobile phase was a 60:40 (v/v) mixture of freshly made Dichloromethane (ml) 30 30 30 30 30 30 30 30 30

Span 80 (ml) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Glutaraldehyde (ml) 1 1 1 1 1 1 1 1 1

Liquidparaffin (ml) 200 200 200 200 200 200 200 200 200

The symmetrical mean was performed on the best formulation (among AMMM-1 to AMMM-9), namely AMMM-8. The symmetrical mean values of time to peak were 1.17µg/ml (Table III).

Table I. Composition of the AMMM

| Components          | Formulations |
|---------------------|--------------|
|                     | AMMM-1 | AMMM-2 | AMMM-3 | AMMM-4 | AMMM-5 | AMMM-6 | AMMM-7 | AMMM-8 | AMMM-9 |
| Amoxicillin trihydrate (mg) | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   | 1000   |
| Ethyl Cellulose (mg) | 50     | 50     | 50     | 50     | 50     | 50     | 50     | 50     | 50     |
| MG (mg)             | 50     | 50     | 50     | 75     | 75     | 75     | 75     | 100    | 100    |
| Carbomer 934P (mg)  | 50     | 75     | 100    | 50     | 75     | 100    | 50     | 75     | 100    |
| Dichloromethane (ml)| 30     | 30     | 30     | 30     | 30     | 30     | 30     | 30     | 30     |
| Span 80 (ml)        | 0.5    | 0.5    | 0.5    | 0.5    | 0.5    | 0.5    | 0.5    | 0.5    | 0.5    |
| Glutaraldehyde (ml) | 1      | 1      | 1      | 1      | 1      | 1      | 1      | 1      | 1      |
| Liquidparaffin (ml) | 200    | 200    | 200    | 200    | 200    | 200    | 200    | 200    | 200    |

Table II. Description of HPLC graph of the ATH

| Time (h) | Retention Time (min) | Peak Area (n = 3) | Asymmetric factor |
|----------|----------------------|-------------------|------------------|
| 1st      | 4.38                 | 70488             | 1.39             |
| 3rd      | 4.36                 | 67922             | 1.37             |
| 6th      | 4.33                 | 51999             | 1.22             |
| 9th      | 4.29                 | 43905             | 1.18             |

Fig. 2. The chromatogram of plasma sample at 1st h (A), 3rd h (B), 6th h (C), and 10th h (D)
The concentration of ATH in plasma with AMMM-8 after oral administration was represented in Tables IV, V and figure 3.

ATH levels in rabbits were shown to be adequate in vivo animal experiments. In vivo tests in rabbits were performed on the best formulation (among AMMM-1 to AMMM-9), namely AMMM-8. The symmetrical mean $C_{max}$ values of formulation AMMM-8 (25.69±0.11g/ml of ATH) after a single dosage of formulation AMMM-8 (ATH: 44.28mg/kg) were greater than those of pure medicines. The AMMM-8's $T_{max}$ values were discovered to be 6 h. The AUC (0-10h) was found to be 185.1 g.h/ml, whereas the $(AUC)_{0-\infty}$ was found to be 269.1 g.h/ml. 840.42 g.h/ml were found to be the AUMC values. Other pharmacokinetic parameters measured in plasma following oral delivery using AMMM-8 (Table IV).

Fig. 3. Plasma concentration of ATH (AMMM-8) in rabbits (p.o)

| Parameters                          | 1h   | 3h   | 6h   | 9h   |
|-------------------------------------|------|------|------|------|
| Linearly (μg/ml)                    | 2 – 12 | 2 – 12 | 2 – 12 | 2 – 12 |
| Correlation coefficient             | 0.9998 | 0.9996 | 0.9995 | 0.9994 |
| Slope                               | 5128.7 | 4985.7 | 4858.1 | 4101.3 |
| Intercept                           | 712.24 | 699.37 | 685.49 | 646.36 |
| Limit of Detection (μg/ml)          | 0.34  | 0.25  | 0.20  | 0.17  |
| Limit of Quantification (μg/ml)     | 1.17  | 1.40  | 1.10  | 1.06  |
Table IV. The concentration of ATH in plasma from AMMM-8

| Time (hr) | Conc (mg/L) | ln(Cp) | Δ AUC | AUC (mg.hr/L) | Δ AUC | AUC (mg.hr/L) | Conc.t | AUMC |
|-----------|-------------|--------|-------|---------------|-------|---------------|--------|------|
| 0         | 0           | 0.00   | 0     | 0             | 0     | 0             | 0      | 0    |
| 1         | 13.26       | 2.58   | 6.6   | 6.6           | 5.10  | 5.10          | 13.26  | 6.63 |
| 2         | 16.35       | 2.79   | 14.8  | 21.4          | 14.8  | 19.90         | 32.70  | 36.24|
| 3         | 20.31       | 3.01   | 18.3  | 39.8          | 18.3  | 38.10         | 60.93  | 79.51|
| 4         | 24.16       | 3.18   | 22.2  | 62.0          | 22.2  | 60.30         | 96.64  | 139.71|
| 6         | 25.69       | 3.25   | 49.9  | 111.9         | 49.8  | 110.2         | 154.14 | 347.42|
| 8         | 19.66       | 2.98   | 45.4  | 157.2         | 45.1  | 155.2         | 157.28 | 465.56|
| 10        | 11.02       | 2.40   | 30.7  | 187.9         | 29.9  | 185.1         | 110.20 | 424.76|
| Inf       | 0.0         | 84.0   | 271.9 | 269.1         | 84.0  | 269.1         | 840.42 | 840.42|

Table V. Pharmacokinetic parameters estimated with AMMM-8 in plasma when administered orally

| Pharmacokinetic parameter | Drug data (AMMM -8) |
|---------------------------|---------------------|
| C<sub>max</sub> (μg/ml)   | 25.69±0.11          |
| T<sub>max</sub> (h)       | 6.00±0.00           |
| K<sub>a</sub>(h<sup>-1</sup>) | 0.131±0.06         |
| T<sub>1/2</sub> (h)       | 3.547±0.08          |
| (AUC)<sub>0-10</sub> (μg.h/ml) | 185.1±1.28       |
| (AUC)<sub>0-∞</sub> (μg.h/ml) | 269.1±4.68        |
| K<sub>d</sub>(h<sup>-1</sup>) | 3.09±0.02          |
| AUMC (μg.h/ml)            | 840.42±3.25         |
| MRT (h<sup>-1</sup>)      | 10.0±0.00           |
| F                         | 0.7301±0.02         |
| P- Value                  | 0.4095±0.01         |

Values in mean ±SD; trials made (n=3)

Conclusion

A combination of Amoxicillin trihydrate (ATH) with mastic gum was prepared as mucoadhesive microspheres. The best design among prepared AMMM-8 was subjected to in vivo studies in rabbits. The appraisal of ATH was urbanized by RP-HPLC. In vivo animal trials in rabbits revealed good levels of ATH in serum compared to pure ATH. The pharmacokinetic parameters, viz., C<sub>max</sub>, and AUC were enriched related to pure ATH drug. The ATH release from the AMMM was localized from the stomach and appreciable than the pure drug.

Acknowledgment

The authors are thankful to the college management for providing the facilities for performing this research work.

Declaration of Competing Interest

The author declared no conflict of interests.

References

Abdul AH, Bala AG, Chintaginjala H, Manchikanti SP, Kamsali AK and Dasari RR (2020), Equator Assessment of Nanoparticles Using the Design-Expert Software, *International Journal of Pharmaceutical Sciences and Nanotechnology* 13(1): 4766-4772. DOI: org/10.37285/ijpsn.2020.13.1.5

Abdul Ahad H, Sreeramulu J, Padmaja BS, Reddy MN and Prakash PG (2011), Preparation of Fluconazole International Scholarly Research Notices, 2011.

Alkharfy KM, Ahmad A, Khan R and Al-Shagha WM (2015), Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model, *European journal of drug metabolism and pharmacokinetics* 40(3): 319-323.
Andrews, GP, Laverty TP, Jones DSJE Jop and biopharmaceutics (2009), Mucoadhesive polymeric platforms for controlled drug delivery 71(3): 505-518.

Atici EB, Yazar Y, Ağıtș Ç, Rıdvanoğlu N and Karlığa B (2017), Development and validation of stability indicating HPLC methods for related substances and assay analyses of amoxicillin and potassium clavulanate mixtures, Journal of Pharmaceutical and Biomedical Analysis 136: 1-9. doi.org/10.1016/j.jpba.2016.12.032

Beg S, Kohli K, Swain S and Hasnain MS (2012), Development and validation of RP-HPLC method for quantitation of amoxicillin trihydrate in bulk and pharmaceutical formulations using Box-Behnken experimental design, Journal of Liquid Chromatography & Related Technologies 35(3): 393-406. doi.org/10.1080/10826076.2011.601493

Dabos K, Sfika E, Vlatta L and Giannikopoulos G (2010), The effect of mastic gum on Helicobacter pylori: a randomized pilot study, Phytotherapy 17(3-4): 296-299. doi.org/10.1016/j.phymed.2009.09.010

Dimas KS, Pantazis P and Ramanujam R (2012), Chios mastic gum: a plant-produced resin exhibiting numerous diverse pharmaceutical and biomedical properties, in vivo 26(5): 777-785.

Hoffman ASI Address (2013), Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation 65(1): 10-16. doi.org/10.1016/j.addr.2012.11.004

Kousar S, Ahad HA, Chinthaginjala H, Babafakuuddin P, Lakunde J and Tanur K (2022), Gas Generating Floating Tablets: A Quick Literature Review for the Scholars, Asian Journal of Research in Chemistry 15(2): 171-175.

Limousy L, Ghouma I, Ouederni A and Jeguirim M (2017), Amoxicillin removal from aqueous solution using activated carbon prepared by chemical activation of olive stone, Environmental science and pollution research 24(11): 9993-10004.

Megoulas NC, Koupparis MAJA and Chemistry B (2005), Development and validation of a novel HPLC/ELSD method for the direct determination of tobramycin in pharmaceuticals, plasma and urine 382(2): 290-296.

Miyamoto T, Okimoto T and Kuwano M (2014), Chemical composition of the essential oil of mastic gum and their antibacterial activity against drug-resistant Helicobacter pylori, Natural products and bioprospecting 4(4): 227-231.

Nagae M, Ikeda T, Mikami Y, Hase H, Ozawa H, Matsuda KI, Kubo T (2007), Intervertebral disc regeneration using platelet-rich plasma and biodegradable gelatin hydrogel microspheres, Tissue engineering 13(1): 147-158. doi.org/10.1089/ten.2006.0042

Nair AB and Jacob S (2016), A simple practice guide for dose conversion between animals and human, Journal of basic and clinical pharmacy 7(2): 27. doi: 10.4103/0976-0105.177703

Narenderan S, Babu B, Gokul T and Meyyanathan SN (2019), A novel simultaneous estimation of sofosbuvir and velpatasvir in human plasma by liquid chromatography tandem-mass spectrometry after protein precipitation method, Current Pharmaceutical Analysis 15(7): 710-715. doi.org/10.2174/157341291466180910102353

Prabhaharan M and Gong SJCP (2008), Novel thiolated carboxymethyl chitosan-ß-cyclodextrin as mucoadhesive hydrophobic drug delivery carriers 73(1): 117-125. doi.org/10.1016/j.carbpol.2007.11.005

Prakash K, Raju PN, KumariKS and Narasu ML (2008), Spectrophotometric estimation of amoxicillin trihydrate in bulk and pharmaceutical dosage form, E-Journal of chemistry 5(S2): 1114-1116. doi.org/10.1155/2008/350646

Purohit TJ, Hanning SM, Amirapu S and Wu Z (2021), Rectal bioavailability of amoxicillin sodium in rabbits: Effects of suppository base and drug dose, Journal of controlled release 338: 858-869. doi.org/10.1016/j.jconrel.2021.09.015

Purohit TJ, Wu Z and Hanning SM (2020), Simple and reliable extraction and a validated high performance liquid chromatographic assay for quantification of amoxicillin from plasma, Journal of Chromatography A 1611: 460-611. doi.org/10.1016/j.chroma.2019.460611
Pushparaj Selvadoss P, Nellore J, Balaraman Ravindran, M., and Sekar U (2018), Novel pyochelin-based PEGylated liposomes for enhanced delivery of antibiotics against resistant clinical isolates of Pseudomonas aeruginosa. Artificial cells, nanomedicine and biotechnology 46(8): 2043-2053. doi.org/10.1080/21691401.2017.1408119

Rocha MBS, De Nucci G, Lemos FN, de Albuquerque Lima Babadopulos RF, Rohleder AVP, Fechine FV, de Moraes MO (2019), Impact of bariatric surgery on the pharmacokinetics parameters of amoxicillin, Obesity Surgery 29(3): 917-927.

Sartini I, Lebkowska-Wieruszewska B, Fadel C, Lisowski A, Poapolathep A and Giorgi M (2022), Single and multiple oral amoxicillin treatment in geese: a pharmacokinetic evaluation, British Poultry Science, pp 1-6. doi.org/10.1080/00071668.2022.2036699

Sharma M, Parmar K, Baria A, Patel TM, Lalani R and Parikh RK (2015), Gastro retentive tablet of febuxostat: formulation, drug release dynamics and factorial design, World J Pharm Res 4(1): 1063-1082.

Shin JW, Seol IC and Son CG (2010), Interpretation of animal dose and human equivalent dose for drug development, The Journal of Korean Medicine 31(3): 1-7.

Shravani Y, Ahad HA, Haranath C, Musa GBM, Adam AA O and Reddy KR (2020), In vitro Relative examination of Dissimilar brands of Rabeprazole sodium Gastro-Resistant Tablets, Int. J. Life Sci. Pharma Res. 10(5): 1-5.

Soares ALP, Montanha MC, Alcantara Cd, Silva SR, Kuroda CM, Yamada SS, Simões CF (2021), Pharmacokinetics of amoxicillin in obese and nonobese subjects, British Journal of Clinical Pharmacology 87(8): 3227-3233. https://doi.org/10.1111/bcp.14739

Sowjanya Hatthi Belgal Mundarinti, Hindustan Abdul Ahad (2022), Central Composite Design Screened Mastic Gum Abetted Mucoadhesive Microspheres of Amoxicillin Trihydrate for Exterminating H. pylori, Advances in Pharmacology and Pharmacy 10(3): 199-208.

Yu S, Li S, Yang H, Lee F, Wu JT and Qian MG (2005), A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery 19(2): 250-254. https://doi.org/10.1002/rcm.177